(AVDL) Avadel Pharmaceuticals - Ratings and Ratios
Exchange: NASDAQ • Country: Ireland • Currency: USD • Type: Common Stock • ISIN: US05337M1045
AVDL: Sleep, Narcolepsy, Treatment, Pharmaceuticals, Biotech
Avadel Pharmaceuticals PLC (NASDAQ: AVDL) is a biopharmaceutical company focused on developing and commercializing medications for chronic and rare diseases. Its lead product candidate, LUMRYZ, is a novel formulation of sodium oxybate, currently in Phase 3 clinical trials. This drug is targeting excessive daytime sleepiness and cataplexy in adults with narcolepsy, a condition affecting an estimated 1 in 2,000 people in the U.S. The company’s approach aims to improve upon existing treatments by potentially offering a more convenient or tolerable option for patients.
From a financial perspective, Avadel Pharmaceuticals operates with a market capitalization of approximately $1.27 billion USD. The stock trades on the NASDAQ exchange under the ticker AVDL. The company’s forward P/E ratio of 34.72 suggests investor expectations for significant growth, though its current P/E is not meaningful due to net losses. The price-to-book ratio of 10.33 indicates a premium valuation relative to its book value, which could reflect optimism about its pipeline. The price-to-sales ratio of 5.66 highlights the market’s confidence in its future revenue potential.
Originally known as Flamel Technologies SA, the company rebranded as Avadel Pharmaceuticals in January 2017 to reflect its sharper focus on pharmaceutical development. Incorporated in 2015 and headquartered in Dublin, Ireland, Avadel has positioned itself as a player in the specialty pharmaceutical space. Its strategic focus on central nervous system disorders, particularly narcolepsy, places it in a niche market with limited competition but significant unmet medical need.
Additional Sources for AVDL Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
AVDL Stock Overview
Market Cap in USD | 1,267m |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
GiC Sub-Industry | Pharmaceuticals |
IPO / Inception | 1996-06-07 |
AVDL Stock Ratings
Growth 5y | 14.0% |
Fundamental | -29.1% |
Dividend | 0.0% |
Rel. Strength Industry | -48.7 |
Analysts | 4.7/5 |
Fair Price Momentum | 6.41 USD |
Fair Price DCF | - |
AVDL Dividends
No Dividends PaidAVDL Growth Ratios
Growth Correlation 3m | -58.2% |
Growth Correlation 12m | -90% |
Growth Correlation 5y | 58.3% |
CAGR 5y | 8.56% |
CAGR/Max DD 5y | 0.09 |
Sharpe Ratio 12m | -0.85 |
Alpha | -57.96 |
Beta | 0.85 |
Volatility | 73.09% |
Current Volume | 712.6k |
Average Volume 20d | 1244.2k |
As of March 15, 2025, the stock is trading at USD 8.33 with a total of 712,614 shares traded.
Over the past week, the price has changed by +5.31%, over one month by -3.25%, over three months by -23.79% and over the past year by -48.26%.
Probably not. Based on ValueRay Fundamental Analyses, Avadel Pharmaceuticals (NASDAQ:AVDL) is currently (March 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -29.12 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of AVDL as of March 2025 is 6.41. This means that AVDL is currently overvalued and has a potential downside of -23.05%.
Avadel Pharmaceuticals has received a consensus analysts rating of 4.70. Therefor, it is recommend to buy AVDL.
- Strong Buy: 7
- Buy: 3
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, AVDL Avadel Pharmaceuticals will be worth about 7.2 in March 2026. The stock is currently trading at 8.33. This means that the stock has a potential downside of -13.21%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 24.7 | 196.5% |
Analysts Target Price | 24.7 | 196.5% |
ValueRay Target Price | 7.2 | -13.2% |